Therapeutic effects of KRM-II-81, positive allosteric modulator for α2/3 subunit containing GABAA receptors, in a mouse model of Dravet syndrome
Introduction: Dravet syndrome (DS) is an intractable epilepsy syndrome concomitant with neurodevelopmental disorder that begins in infancy. DS is dominantly caused by mutations in the SCN1A gene, which encodes the α subunit of a voltage-gated Na channel. Pre-synaptic inhibitory dysfunction is regard...
Main Authors: | Sachiko Nakakubo, Yasuyoshi Hiramatsu, Takeru Goto, Syuhei Kimura, Masashi Narugami, Midori Nakajima, Yuki Ueda, Hideaki Shiraishi, Atsushi Manabe, Dishary Sharmin, James M. Cook, Kiyoshi Egawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1273633/full |
Similar Items
-
Efficacy and tolerability of add‐on stiripentol in real‐world clinical practice: An observational study in Dravet syndrome and non‐Dravet developmental and epileptic encephalopathies
by: Antonio Gil‐Nagel, et al.
Published: (2024-02-01) -
Acute effect of antiseizure drugs on background oscillations in Scn1aA1783V Dravet syndrome mouse model
by: Shir Quinn, et al.
Published: (2023-03-01) -
Fenfluramine Add-On Therapy of Dravet Syndrome
by: J Gordon Millichap
Published: (2012-08-01) -
Dravet Syndrome—The Polish Family’s Perspective Study
by: Justyna Paprocka, et al.
Published: (2021-04-01) -
A review of fenfluramine for the treatment of Dravet syndrome patients
by: Kayla Simon, et al.
Published: (2022-01-01)